XENPOZYME: payments to doctors
Payments that named XENPOZYME as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $449K
- Providers
- 367
- Transactions
- 783
- Average per transaction
- $573
The per-transaction average — $573 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 367 providers the average total is $1,223, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $412,014 | 91.8% |
| Sanofi-aventis U.S. LLC | $23,658 | 5.3% |
| Sanofi US Services Inc. | $13,014 | 2.9% |